Dasatinib dosage and evidence

What is Dasatinib?

How does Dasatinib work?

It blocks survival signals inside worn-out cells, so they die. It works best alongside quercetin.

What do people who took Dasatinib report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• It is essentially never discussed alone. The pattern described is short intermittent courses paired with quercetin, and often with fisetin or azithromycin added, on a schedule of a couple of days of dosing followed by weeks off and repeated. No self-report in this material isolates this drug from the others.
• The most commonly reported experience is mild fatigue on the day of dosing, lasting about a day, and several people describe no side effects at all at these intermittent doses.
• The argument made repeatedly, and it is the load-bearing assumption of the whole practice, is that the serious toxicity attached to this drug comes from continuous daily use in cancer treatment over years rather than from two days at a time. That is a reasoning step people state openly, not something established in the discussion.
• What almost nobody reports is a noticeable effect. The discussion is about tolerability and protocol, not about anything felt or measured, and the people posting generally say so.
• Prescription access is the practical obstacle described, and third party knowledge bases assembled by longevity foundations are treated as the reference point rather than any individual's experience.
• Attempts to measure an outcome are described using epigenetic age clocks, and posters in the same threads dispute whether those readouts mean anything, so even the measured reports are contested inside the community that produced them.

Sources: Senolytics and dosing threads on LongeCity, reached through site-restricted search extracts of the threads because the site itself would not load from this environment, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The evidence, in charts

The studies we cite

• Study in people2024
  Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial

  The strongest senolytic trial run so far came out negative. 60 postmenopausal women were given either dasatinib with quercetin, or nothing. After 20 weeks, the blood marker of bone breakdown that the whole trial was built around had not separated between the groups. Bone was a sensible place to look, because worn-out cells are thought to drive bone loss. It did not work out.

  60 postmenopausal women randomised to dasatinib plus quercetin or control: the primary endpoint, change in the bone resorption marker CTx at 20 weeks, did not differ between groups.

  PMID 38956196 Nature Medicine
• Study in people2023
  Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: a phase I, single-blind, randomized, placebo-controlled pilot trial

  A pilot that looked positive lost its effect the moment a dummy group was added. The same team ran it again in twelve people with lung scarring. Frailty, lung function and physical function did not meaningfully separate. The people on the drugs reported 65 non-serious side effects against 22 on the dummy. Small numbers, and a clear lesson about how much to trust an uncontrolled pilot.

  The same team's open-label pilot repeated with a placebo arm, n=12: frailty, pulmonary and physical function did not appear to differ meaningfully between groups, and the drug arm reported 65 non-serious adverse events against 22 on placebo.

  PMID 36857968 EBioMedicine
• Study in people2019
  Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease

  This is the first evidence in people that the combination actually clears worn-out cells. Patients with diabetic kidney disease took it briefly, and within days the burden of those cells fell, along with the inflammatory signals they release. What it does not show is any benefit to the patients. Clearing the cells is the theory. Whether anyone feels or functions better is the test.

  First human evidence that D+Q reduces senescent-cell burden and SASP factors within days.

  PMID 31542391 EBioMedicine
• Study in people2019
  Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study

  An early study in 14 people with lung scarring found their physical function improved. Everybody knew they were taking the drugs and there was no comparison group. Side effects were mostly mild to moderate. Read this as the study that justified running a proper trial, and then read what the proper trial went on to find.

  Open-label pilot in 14 IPF patients: improved physical function measures; adverse events mostly mild to moderate.

  PMID 30616998 EBioMedicine
• Animal study2015
  The Achilles' heel of senescent cells: from transcriptome to senolytic drugs

  In mice: dasatinib cleared worn-out cells. With quercetin, it helped old mice, and mice bred to age fast, function better.

  Dasatinib selectively cleared senescent cells and, combined with quercetin, improved function in aged and progeroid mice.

  PMID 25754370 Aging Cell
• Animal study2018
  Senolytics improve physical function and increase lifespan in old age

  In old mice: D+Q given every so often helped them move and function better. From the point treatment began, they lived about 36 percent longer.

  Intermittent D+Q in old mice improved physical function and extended remaining lifespan by about 36%.

  PMID 29988130 Nature Medicine